BLA 125422 · Thrombogenics, INC
Jetrea
Ocriplasmin · Intravitreal
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 22, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Oct 17, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
23
4 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 13, 2014 Supplement 25 · Efficacy · priority review LabelLetter
- Oct 17, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewPediatric Medical Review
1 products under this application
- JETREA · OCRIPLASMIN 2.5MG/ML · INJECTABLE, INTRAVITREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ocriplasmin" as an intervention, any sponsor and status, largest first.
Alcon ResearchIndustry
NCT02035748 · 628 participants · Start Apr 2014 · Primary completion Sep 2015
Drug: Ocriplasmin · For: Vitreomacular Traction; Vitreomacular Adhesion
- Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.Pivotal-lookingCompleted
ThromboGenicsIndustry
NCT00781859 · 326 participants · Start Dec 2008 · Primary completion Mar 2010
Drug: 125 µg Ocriplasmin; Placebo · For: Vitreomacular Adhesion
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 41 sites in all
- Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.Pivotal-lookingCompleted
ThromboGenicsIndustry
NCT00798317 · 326 participants · Start Dec 2008 · Primary completion Jun 2010
Drug: Ocriplasmin 125µg; Placebo · For: Vitreomacular Adhesion
Sites: Campbell, California; San Francisco, California; Santa Barbara, California · 48 sites in all
- A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular AdhesionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01889251 · 251 participants · Start Jul 2013 · Primary completion Sep 2014
Drug: Ocriplasmin; Sham injection · For: Symptomatic Vitreomacular Adhesion
Sites: Tokyo, Japan
- Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular HolePivotal-lookingCompleted
ThromboGenicsIndustry
NCT01429441 · 220 participants · Start Oct 2011 · Primary completion Oct 2014
Drug: Ocriplasmin · For: Vitreomacular Adhesion Including Macular Hole
Sites: Phoenix, Arizona; Beverly Hills, California; Sacramento, California · 25 sites in all
- A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)Pivotal-lookingCompleted
ThromboGenicsIndustry
NCT00412958 · 125 participants · Start Dec 2006 · Primary completion Oct 2008
Drug: Ocriplasmin 25µg; Ocriplasmin 75µg and 2 more · For: Vitrectomy
Sites: Tucson, Arizona; Huntington Beach, California; Los Angeles, California · 20 sites in all
- Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular AdhesionPivotal-lookingCompleted
ThromboGenicsIndustry
NCT00913744 · 100 participants · Start Jan 2010 · Primary completion Dec 2012
Drug: Ocriplasmin; Sham injection · For: Exudative Age-Related Macular Degeneration; Focal Vitreomacular Adhesion
Sites: Beverly Hills, California; Sacramento, California; Aurora, Colorado · 27 sites in all
Alcon ResearchIndustry
NCT02322229 · 62 participants · Start May 26, 2015 · Primary completion Dec 11, 2015
Drug: Ocriplasmin 0.125 mg in a 0.1 mL volume · For: Vitreomacular Traction; Vitreomacular Adhesion
Sites: New South Wales, Australia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ocriplasmin for symptomatic vitreomacular adhesion.
Neffendorf JE, Kirthi V, Pringle E, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.
Kaiser PK, Kampik A, Kuppermann BD, et al. · Retina 2015 · Clinical Trial, Phase III, Multicenter Study
- Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials.
Jackson TL, Haller J, Blot KH, et al. · Surv Ophthalmol 2022 · Meta-Analysis, Systematic Review
- Intravitreal gas for symptomatic vitreomacular adhesion: a synthesis of the literature.
Neffendorf JE, Simpson ARH, Steel DHW, et al. · Acta Ophthalmol 2018 · Systematic Review
- The efficacy and safety of ocriplasmin for patients with vitreous macular traction.
Zhang WF, Zhao XY, Meng LH, et al. · Acta Ophthalmol 2022 · Meta-Analysis
- Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials.
Khanani AM, Constantine RN, Blot KH, et al. · Acta Ophthalmol 2021 · Meta-Analysis, Systematic Review
Sponsor: Thrombogenics, INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.